Introduction.Enterococcus faecium is a commensal organism commonly colonizing the human gastrointestinal tract. Although it is generally a non-virulent organism, E. faecium can cause significant morbidity and mortality due to its inherent and acquired resistances to commonly used antimicrobials. Patients who are immunosuppressed are particularly vulnerable.
Case presentation. A 65–75-year-old patient with a history of an orthotopic liver transplant for hepatitis C infection and diabetes was re-admitted to the hospital with abdominal pain and fever. The patient had several recent admissions related to the presentation reported here, which included treatment with a prolonged course of broad-spectrum antibiotics. The patient was found to have a recurrent liver abscess and blood cultures grew vancomycin-resistant E. faecium, non-susceptible to all tested agents: ampicillin, penicillin, vancomycin, daptomycin and linezolid. The patient was started initially on chloramphenicol intravenously while awaiting additional susceptibility testing, which ultimately revealed chloramphenicol non-susceptibility. Tigecycline was started but the patient ultimately decided to pursue hospice care.
Conclusion. Multi-drug-resistant organisms are increasingly being recognized and are associated with poorer outcomes, particularly in immunosuppressed patients. We describe a particularly resistant organism and discuss potential therapeutic options.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PrematungeC, MacDougallC, JohnstoneJ, AdomakoK, LamF et al. VRE and VSE bacteremia outcomes in the era of effective vre therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol2016; 37:26–35 [View Article][PubMed]
PatelG, SnydmanDR. AST Infectious Diseases Community of Practice Vancomycin-resistant Enterococcus infections in solid organ transplantation. Am J Transplant2013; 13 (Suppl. 4):59–67 [View Article][PubMed]
MermelLA, AllonM, BouzaE, CravenDE, FlynnP et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009. Update by the Infectious Diseases Society of America. Clin Infect Dis2009; 49:1–45 [View Article][PubMed]
FDA.FDA Warns of Increased Risk of Death with IV Antibacterial Tygacil (Tigecycline) and Approves New Boxed Warning. Silver Spring, MD:: U.S. Food and Drug Administration;; 2013
AriasCA, MendesRE, StilwellMG, JonesRN, MurrayBE. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis2012; 54:S233–S238 [View Article][PubMed]
StryjewskiME, GrahamDR, WilsonSE, O'RiordanW, YoungD et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis2008; 46:1683–1693 [View Article][PubMed]
LynchC, CourvalinP, NikaidoH. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother1997; 41:869–871 [View Article][PubMed]